Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
Metrics: PDF 1108 views | HTML 2072 views | ?
Zhenhua Zhu1, Zheng Jin2, Mei Zhang3, Yajun Tang3, Guang Yang1, Xiaowei Yuan1, Jihang Yao1 and Dahui Sun1
1Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China
2Department of Immunology, College of Basic Medical sciences, Jilin University, Changchun, China
3College of Chemistry, Jilin University, Changchun, China
Dahui Sun, email: email@example.com
Keywords: programmed death-ligand 1, sarcoma, prognosis, survival, meta-analysis
Received: May 23, 2017 Accepted: June 30, 2017 Published: July 11, 2017
Background: The prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of PD-L1 on clinicopathlogical findings and survival outcomes in sarcoma.
Materials and Methods: A comprehensive search in PubMed, Embase and the Cochrane Library was conducted for relevant studies. The odds ratios or hazard ratios, at 95% confidence intervals were used as measures for investigation of the correlation between PD-L1 expression and clinicopathlogical features or survival outcomes.
Results: Fourteen eligible studies comprising 868 patients were selected for analysis. Pooled hazard ratios indicated that the association of PD-L1 expression with overall survival in bone sarcoma (osteosarcoma and chondrosarcoma) patients was statistically significant (1.987, 95% CI: 1.224–3.224, p = 0.005), as was its association with event-free survival in bone and soft-tissue sarcoma patients (3.868, 95% CI: 2.298–6.511, p = 0.000). Additionally, the expression of PD-L1 was positively correlated with the infiltration of programmed death 1 (PD-1) positive T-lymphocytes (OR: 4.012, 95% CI: 2.391–6.733, p = 0.000).
Conclusions: Our meta-analysis indicated that high PD-L1 expression is likely to be a negative factor for patients with sarcomas and that it predicts worse survival outcomes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.